NCT06580288 (FIGHT) is a Phase 3 clinical trial of Finerenone in IgA Nephropathy, sponsored by Zhejiang University.

Who is sponsoring NCT06580288?

NCT06580288 is sponsored by Zhejiang University.

What drugs are being tested in NCT06580288?

Interventions in NCT06580288: Finerenone, Placebo.

What condition does NCT06580288 study?

NCT06580288 studies IgA Nephropathy.

Is NCT06580288 still recruiting?

NCT06580288 is currently not yet recruiting. Last updated 30 August 2024.

Last reviewed 2024-08-30 · How we verify

NCT06580288: FIGHT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Finerenone in IgA Nephropathy

Not yet recruiting Phase 3 Last updated 30 August 2024

What this trial tests

Phase 3 trial testing Finerenone in IgA Nephropathy in 120 participants. Not yet recruiting.

Timeline

8 October 2024

Primary endpoint
8 June 2026

8 October 2026

Quick facts

Lead sponsor	Zhejiang University
Phase	Phase 3
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	120
Start date	8 October 2024
Primary completion	8 June 2026
Estimated completion	8 October 2026

Drugs / interventions tested

Finerenone (FINERENONE) — full drug profile →
Placebo

Conditions studied

IgA Nephropathy — all drugs for IgA Nephropathy →

Sponsor

Zhejiang University

Who can join

18 and older, any sex, with IgA Nephropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this trial is to conduct a randomized, multicenter, placebo-controlled, double-blind clinical trial to determine the safety and efficacy of Finerenone in reducing proteinuria and protecting renal function in patients with IgA nephropathy. The primary endpoint event was the change in urinary albumin/creatinine ratio between the two groups at 12 months of treatment.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Finerenone: Potential Clinical Application Across the Spectrum of Cardiovascular Disease and Chronic Kidney Disease.
Haq N, Uppal P, Abedin T, Lala A. · · 2025 · cited 1× · PMID 40364247 · DOI 10.3390/jcm14093213
New and Emerging Nonimmunosuppressive Drug Therapies for Primary Adult Glomerular Diseases.
Mushailov V, Radhakrishnan J. · · 2025 · PMID 42165056 · DOI 10.1016/j.xkme.2025.101133
Finerenone in IgA nephropathy: real-world 12-month propensity-matched cohort demonstrating proteinuria reduction, eGFR preservation, and safety profile.
Zhang W, Yu JT, Lin B, Shen X, et al · · 2026 · PMID 42002725 · DOI 10.1080/0886022x.2026.2644719

Verify or expand the search:

Other trials of Finerenone

Trials testing the same drug.

NCT07547878 — Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) · Phase 4 · not yet recruiting
NCT07351864 — Finerenone Plus SGLT2 Inhibitors in Heart Failure · Phase 4 · not yet recruiting
NCT07326631 — Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure · NA · not yet recruiting
NCT07235891 — Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease · Phase 4 · not yet recruiting
NCT07056595 — Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial · NA · recruiting

Other recruiting trials for IgA Nephropathy

Currently open trials in the same condition.

NCT07030894 — Nefecon and Ambrisentan in IgA Nephropathy · Phase 4 · recruiting
NCT06740526 — Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue · Phase 2 · recruiting
NCT06767592 — A Study of Probiotics in IgA Nephropathy · NA · recruiting
NCT05852938 — A Study of Zigakibart in Adults With IgA Nephropathy · Phase 3 · active not recruiting
NCT05942625 — A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects · Phase 1 · recruiting

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06580288 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 30 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06580288.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing